bioXXmed AG is a German investment holding company focused on the biotechnology and medical technology sectors. It directs equity and debt capital into innovative firms developing products aimed at diagnosing, alleviating, or curing diseases. Established in 2000 and formerly known as Cytotools AG until its rebranding in 2022, bioXXmed AG engages as an active portfolio manager, collaborating closely with the management of its investments to support their success and long-term viability. The company itself does not conduct research and development directly; instead, it finances biomedical projects through its subsidiary companies, which remain legally independent. Notably, bioXXmed AG holds a majority stake in DermaTools Biotech GmbH and is the largest shareholder in Cytopharma GmbH, underlining its strategic role in advancing medical innovation via capital investment and portfolio management.